UCLA's AI Platform Tests Cancer Drugs on Patient Tumors

Imagine if doctors could test cancer treatments on your actual tumor cells before you ever started therapy, sparing you from drugs that won't work and finding the ones that will.

That future just got closer. Researchers at UCLA Health have developed a platform that combines 3D bioprinting, advanced imaging, and artificial intelligence to rapidly test cancer therapies on tiny, lab-grown replicas of patient tumors called organoids.

The system addresses a major challenge in cancer care. While tumor organoids have become powerful research tools because they closely resemble real patient tumors, existing methods struggle to test treatments quickly and at the scale needed for clinical use.

UCLA's new approach changes that. The platform uses 3D bioprinting to create thousands of patient-derived tumor organoids, then continuously monitors how each one responds to different drugs in real time. Special imaging technology tracks the organoids without using dyes or destructive tests that can alter cell behavior.

Artificial intelligence analyzes the massive amounts of data, tracking individual organoid responses and identifying patterns that reveal which therapies might work best. The system published in Nature Protocols can evaluate hundreds of potential treatments simultaneously.

"Instead of asking whether a drug works on average for a large number of tumor cells, we can now determine which specific organoids respond and which do not," said Dr. Michael Teitell, director of the UCLA Health Jonsson Comprehensive Cancer Center and co-senior author of the study.

The technology has already successfully measured drug responses in both established cancer cell lines and actual patient-derived tumor samples. Researchers can now detect rare resistant tumor populations and track how treatments work over time at the level of individual organoids.

The Ripple Effect

This breakthrough could transform treatment for patients with rare and hard-to-treat cancers who often face limited options. By testing drugs on a patient's own tumor cells before treatment begins, doctors could avoid ineffective therapies that waste precious time and cause unnecessary side effects.

The platform also helps researchers understand why some tumors respond to treatment while others resist, potentially uncovering new therapeutic strategies. The work was funded by the Air Force Office of Scientific Research, the Department of Defense, the National Science Foundation, and the National Institutes of Health.

Personalized cancer care is moving from promise to reality, one organoid at a time.